Growth factors as therapeutic targets in HCC

Critical Reviews in Oncology/Hematology

Volumn 67, Issue 1, 2008, Pages 8-15

  Furuse, Junji ^a  

^a School of Medicine   (Japan)

Author keywords

Epidermal growth factor receptor; Hepatocellular carcinoma; Vascular endothelial growth factor

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEMCITABINE; LAPATINIB; OXALIPLATIN; PLACEBO; SORAFENIB; SUNITINIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ABDOMINAL PAIN; ACNE; ADVANCED CANCER; AMYLASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ASCITES; ASTHENIA; BILIRUBIN BLOOD LEVEL; BLEEDING; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE CONTROL; DIZZINESS; DRUG EFFICACY; EPISTAXIS; FATIGUE; FEVER; GASTROINTESTINAL HEMORRHAGE; GENE TARGETING; HAND FOOT SYNDROME; HEMATOCHEZIA; HEMORRHAGIC ASCI; HEPATOMA CELL; HUMAN; HYPERBILIRUBINEMIA; HYPERKALEMIA; HYPERTENSION; HYPOALBUMINEMIA; HYPOMAGNESEMIA; INTESTINE PERFORATION; LIVER CELL CARCINOMA; LYMPHOCYTOPENIA; METASTASIS; MONOTHERAPY; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PROTEINURIA; PRURITUS; RASH; RECOMMENDED DRUG DOSE; REVIEW; SEPSIS; SIDE EFFECT; STOMACH ULCER; THROMBOCYTOPENIA; TRANSIENT ISCHEMIC ATTACK; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VOMITING; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS AS TOPIC; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS;

EID: 44649116436     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2008.02.009     Document Type: Review

References (53)

1. Parkin D.M., Pisani P., and Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 80 6 (1999) 827-841
2. McGlynn K.A., Tsao L., Hsing A.W., Devesa S.S., and Fraumeni Jr. J.F. International trends and patterns of primary liver cancer. Int J Cancer 94 2 (2001) 290-296
3. Number of deaths and proportional mortality rates from malignant neoplasms by site in Japan; 2003. http://www.fpcr.or.jp/publication/pdf/statistics2005.pdf (accessed 10 May, 2007).
4. Ikai I., Arii S., Ichida T., et al. Report of the 16th follow-up survey of primary liver cancer. Hepatol Res 32 3 (2005) 163-172
5. El-Serag H.B., and Mason A.C. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340 10 (1999) 745-750
6. Bruix J., and Llovet J.M. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 35 3 (2002) 519-524
7. Lai C.L., Wu P.C., Chan G.C., Lok A.S., and Lin H.J. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 62 3 (1988) 479-483
8. Colleoni M., Nole F., Di Bartolomeo M., de Braud F., and Bajetta E. Mitoxantrone in patients affected by hepatocellular carcinoma with unfavorable prognostic factors. Oncology 49 2 (1992) 139-142
9. Leung T.W., Patt Y.Z., Lau W.Y., et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 5 7 (1999) 1676-1681
10. Ikeda M., Okusaka T., Ueno H., Takezako Y., and Morizane C. A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma. Cancer 103 4 (2005) 756-762
11. Boucher E., Corbinais S., Brissot P., Boudjema K., and Raoul J.L. Treatment of hepatocellular carcinoma (HCC) with systemic chemotherapy combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF regimen). Cancer Chemother Pharmacol 50 4 (2002) 305-308
12. Patt Y.Z., Hassan M.M., Lozano R.D., et al. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol 21 3 (2003) 421-427
13. Yeo W., Mok T.S., Zee B., et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 97 20 (2005) 1532-1538
14. Ando E., Tanaka M., Yamashita F., et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 95 3 (2002) 588-595
15. Ota H., Nagano H., Sakon M., et al. Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. Br J Cancer 93 5 (2005) 557-564
16. Woodburn J.R. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 82 2-3 (1999) 241-250
17. Gibbs J.B. Anticancer drug targets: growth factors and growth factor signaling. J Clin Invest 105 1 (2000) 9-13
18. Hung W.C., Chuang L.Y., Tsai J.H., and Chang C.C. Effects of epidermal growth factor on growth control and signal transduction pathways in different human hepatoma cell lines. Biochem Mol Biol Int 30 2 (1993) 319-328
19. Daveau M., Scotte M., Francois A., et al. Hepatocyte growth factor, transforming growth factor alpha, and their receptors as combined markers of prognosis in hepatocellular carcinoma. Mol Carcinog 36 3 (2003) 130-141
20. Morimitsu Y., Hsia C.C., Kojiro M., and Tabor E. Nodules of less-differentiated tumor within or adjacent to hepatocellular carcinoma: relative expression of transforming growth factor-alpha and its receptor in the different areas of tumor. Hum Pathol 26 10 (1995) 1126-1132
21. Ito Y., Takeda T., Sakon M., et al. Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br J Cancer 84 10 (2001) 1377-1383
22. Noonberg S.B., and Benz C.C. Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents. Drugs 59 4 (2000) 753-767
23. Philip P.A., Mahoney M.R., Allmer C., et al. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 23 27 (2005) 6657-6663
24. Thomas M.B., Dutta A., Brown T., et al. A phase II open-label study of OSI-774 (NSC 718781) in unresectable hepatocellular carcinoma. J Clin Oncol, 2005 Proc Am Soc Clin Oncol 23 (2005) 317s [abstr 4038]
25. Ramanathan R.K., Belani C.P., Singh D.A., et al. Phase II study of lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase 1 and 2 (Her2/Neu) in patients (pts) with advanced biliary tree cancer (BTC) or hepatocellular cancer (HCC). A California Consortium (CCC-P) Trial. J Clin Oncol, 2006 Proc Am Soc Clin Oncol 24 (2006) 181s [abstr 4010]
26. Gruenwald V., Wilkens L., Gebel M., et al. A phase II open-label study of cetuximab in unresectable hepatocellular carcinoma: final results. J Clin Oncol, 2007 Proc Am Soc Clin Oncol 25 (2007) 222s [abstr 4598]
27. Zhu A.X., Stuart K., Blaszkowsky L.S., et al. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer 110 (2007) 581-589
28. Louafi S., Hebber M., Rosmorduc O., et al. Gemcitabine, oxaliplatin (GEMOX) and cetuximab for treatment of hepatocellular carcinoma (HCC): results of the phase II study ERGO. J Clin Oncol, 2007 Proc Am Soc Clin Oncol 25 (2007) 221s [abstr 4594]
29. Huether A., Hopfner M., Baradari V., Schuppan D., and Scherubl H. EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer. Biochem Pharmacol 70 11 (2005) 1568-1578
30. Miura H., Miyazaki T., Kuroda M., et al. Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma. J Hepatol 27 5 (1997) 854-861
31. Yamaguchi R., Yano H., Iemura A., Ogasawara S., Haramaki M., and Kojiro M. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 28 1 (1998) 68-77
32. Chao Y., Li C.P., Chau G.Y., et al. Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann Surg Oncol 10 4 (2003) 355-362
33. Poon R.T., Lau C.P., Ho J.W., Yu W.C., Fan S.T., and Wong J. Tissue factor expression correlates with tumor angiogenesis and invasiveness in human hepatocellular carcinoma. Clin Cancer Res 9 14 (2003) 5339-5345
34. Poon R.T., Ho J.W., Tong C.S., Lau C., Ng I.O., and Fan S.T. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg 91 10 (2004) 1354-1360
35. Tong R.T., Boucher Y., Kozin S.V., Winkler F., Hicklin D.J., and Jain R.K. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64 11 (2004) 3731-3736
36. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307 5706 (2005) 58-62
37. Gerber H.P., and Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65 3 (2005) 671-680
38. Schwartz JD, Schwartz M, Lehrer D, et al. Bevacizumab in unresectable hepatocellular carcinoma (HCC) for patients without metastasis and without invasion of the portal vein. J Clin Oncol, 2006 Proc Am Soc Clin Oncol 2006;24:213s [abstr 4144].
39. Malka D, Dromain C, Farace F, et al. Bevacizumab in patients (pts) with advanced hepatocellular carcinoma (HCC): Preliminary results of a phase II study with circulating endothelial cell (CEC) monitoring. J Clin Oncol 2007 Proc Am Soc Clin Oncol 2007;25:215s [abstr 4570].
40. Zhu A.X., Blaszkowsky L.S., Ryan D.P., et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 24 12 (2006) 1898-1903
41. Thomas MB, Chadha R, Iwasaki M, Glover K, Abbruzzese JL. The combination of bevacizumab (B) and erlotinib (E) shows significant biological activity in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol 2007 Proc Am Soc Clin Oncol 2007;25:214s [abstr 4567].
42. Sun W, Haller DG, Mykulowycz K, et al. Combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma (HCC): a phase II study. J Clin Oncol 2007 Proc Am Soc Clin Oncol 2007;25:214s [abstr 4574].
43. Abou-Alfa G.K., Schwartz L., Ricci S., et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24 26 (2006) 293-300
44. Furuse J., Ishii H., Nakachi K., Suzuki E., Shimizu S., and Nakajima K. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 99 1 (2008) 159-165
45. Kanai F, Yoshida H, Teratani T, et al. New feasibility study design with hepatocellular carcinoma: A phase I/II study of TSU-68, an oral angiogenesis inhibitor. J Clin Oncol 2006 Proc Am Soc Clin Oncol 2006;24:213s [abstr 4145].
46. Zhu AW, Sahani DV, di Tomaso E, et al. A phase II study of sunitinib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2007 Proc Am Soc Clin Oncol 2007;25:231s [abstr 4637].
47. Faivre SJ, Raymond E, Douillard J, et al. Assessment of safety and drug-induced tumor necrosis with sunitinib in patients (pts) with unresectable hepatocellular carcinoma (HCC). J Clin Oncol 2007 Proc Am Soc Clin Oncol 2007;25:149s [abstr 3546].
48. Ito Y., Sasaki Y., Horimoto M., et al. Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology 27 4 (1998) 951-958
49. Schmidt C.M., McKillop I.H., Cahill P.A., and Sitzmann J.V. Increased MAPK expression and activity in primary human hepatocellular carcinoma. Biochem Biophys Res Commun 236 1 (1997) 54-58
50. Huynh H., Nguyen T.T., Chow K.H., Tan P.H., Soo K.C., and Tran E. Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol 3 (2003) 19
51. Llovet JM, Ricci S, Mazzaferro V, et al. Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol 2007 Proc Am Soc Clin Oncol 2007;25:962s [abstr LBA 1].
52. Fernando N.H., and Hurwitz H.I. Targeted therapy of colorectal cancer: clinical experience with bevacizumab. Oncologist 9 Suppl. 1 (2004) 11-18
53. Eckel F., and Schmid R.M. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 96 6 (2007) 896-902